1. Volume 52, Issue 5, Pages 1381-1387 (November 2007)
Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression 
Michael Lein, Manfred Wirth, Kurt Miller, Hans-Udo Eickenberg, Lothar Weißbach, Katja Schmidt, Ulrike Haus, Carsten Stephan, Sven Meissner, Stefan A. Loening, Klaus Jung 
European Urology 
Volume 52, Issue 5, Pages (November 2007)
DOI: /j.eururo
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
Changes in mean concentrations of all bone markers and prostate-specific antigen. Zoledronic acid was administered every 4 wk for a 15-mo treatment period. Blood serum for bone markers was collected prior to start of zoledronic acid treatment (week 0) and every 12 wk. The percent of changes related to pretreatment values as shown in Table 1 is presented. (A) Patients without bone progression (n=27). (B) Patients with metastatic bone progression (n=50).
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
Means and 1/5 of standard deviation of bone markers and prostate-specific antigen in patient groups with (-□-) and without (-●-) progression during the entire time course. Y-axes=related to pretreatment values (%). *Significant differences of at least p<0.05 between both groups studied, t test according to Student.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions